This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2010 Mar;51(3):410, 412-3.

doi: 10.1007/s00108-009-2575-8.

[Vaccine against human papillomavirus : PATRICIA Study (PApilloma TRIal against Cancer In young Adults)]

[Article in German]

A M Kaufmann¹, S Nitschmann

Affiliations

Affiliation

¹ Gynäkologische Tumorimmunologie, Gynäkologie, Campus Mitte und Benjamin Franklin, Charité Universitätsmedizin Berlin, Berlin, Deutschland. andreas.kaufmann@charite.de

PMID: 20127302
DOI: 10.1007/s00108-009-2575-8

[Vaccine against human papillomavirus : PATRICIA Study (PApilloma TRIal against Cancer In young Adults)]

[Article in German]

A M Kaufmann et al. Internist (Berl). 2010 Mar.

. 2010 Mar;51(3):410, 412-3.

doi: 10.1007/s00108-009-2575-8.

Authors

A M Kaufmann¹, S Nitschmann

Affiliation

¹ Gynäkologische Tumorimmunologie, Gynäkologie, Campus Mitte und Benjamin Franklin, Charité Universitätsmedizin Berlin, Berlin, Deutschland. andreas.kaufmann@charite.de

PMID: 20127302
DOI: 10.1007/s00108-009-2575-8

No abstract available

PubMed Disclaimer

Similar articles

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group. Paavonen J, et al. Lancet. 2009 Jul 25;374(9686):301-14. doi: 10.1016/S0140-6736(09)61248-4. Epub 2009 Jul 6. Lancet. 2009. PMID: 19586656 Clinical Trial.
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M; HPV PATRICIA Study Group. Wheeler CM, et al. Lancet Oncol. 2012 Jan;13(1):100-10. doi: 10.1016/S1470-2045(11)70287-X. Epub 2011 Nov 8. Lancet Oncol. 2012. PMID: 22075170 Clinical Trial.
Evaluation of the interim analysis from the PATRICIA study group: efficacy of a vaccine against HPV 16 and 18.
Frederick PJ, Huh WK; PATRICIA Study Group. Frederick PJ, et al. Expert Rev Anticancer Ther. 2008 May;8(5):701-5. doi: 10.1586/14737140.8.5.701. Expert Rev Anticancer Ther. 2008. PMID: 18471043 Review.
Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow SN, Kitchener HC, Teixeira JC, Jaisamrarn U, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Mindel A, de Sutter P, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group. Apter D, et al. Clin Vaccine Immunol. 2015 Apr;22(4):361-73. doi: 10.1128/CVI.00591-14. Epub 2015 Feb 4. Clin Vaccine Immunol. 2015. PMID: 25651922 Free PMC article. Clinical Trial.
Cervical cancer vaccine development.
Frazer IH. Frazer IH. Sex Health. 2010 Sep;7(3):230-4. doi: 10.1071/SH09132. Sex Health. 2010. PMID: 20719210 Review.

See all similar articles

Cited by

Virus-like particles for the prevention of human papillomavirus-associated malignancies.
Wang JW, Roden RB. Wang JW, et al. Expert Rev Vaccines. 2013 Feb;12(2):129-41. doi: 10.1586/erv.12.151. Expert Rev Vaccines. 2013. PMID: 23414405 Free PMC article. Review.
Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
Wang JW, Jagu S, Wang C, Kitchener HC, Daayana S, Stern PL, Pang S, Day PM, Huh WK, Roden RB. Wang JW, et al. PLoS One. 2014 Jul 7;9(7):e101576. doi: 10.1371/journal.pone.0101576. eCollection 2014. PLoS One. 2014. PMID: 24999962 Free PMC article.
Immune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix.
Ferreira Costa AP, Gonçalves AK, Machado PRL, Souza LBFC, Sarmento A, Cobucci RNO, Giraldo PC, Witkin SS. Ferreira Costa AP, et al. Asian Pac J Cancer Prev. 2018 Aug 24;19(8):2313-2317. doi: 10.22034/APJCP.2018.19.8.2313. Asian Pac J Cancer Prev. 2018. PMID: 30141308 Free PMC article.
L2, the minor capsid protein of papillomavirus.
Wang JW, Roden RB. Wang JW, et al. Virology. 2013 Oct;445(1-2):175-86. doi: 10.1016/j.virol.2013.04.017. Epub 2013 May 17. Virology. 2013. PMID: 23689062 Free PMC article. Review.

References

1. N Engl J Med. 2007 May 10;356(19):1915-27 - PubMed
1. Gynecol Oncol. 2009 Dec;115(3 Suppl):S15-23 - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Medical
- MedlinePlus Consumer Health Information
- MedlinePlus Health Information